predomin
aetiolog
agent
common
cold
human
rhinoviru
hrv
lead
caus
human
infecti
diseas
earli
studi
show
monoval
formalininactiv
hrv
vaccin
protect
virusneutr
antibodi
nab
correl
protect
howev
cocircul
mani
hrv
type
discourag
vaccin
effort
test
hypothesi
increas
viru
input
titr
polyval
inactiv
hrv
vaccin
may
result
broad
nab
respons
show
serum
nab
mani
rhinoviru
type
induc
polyval
inactiv
hrv
plu
alhydrogel
alum
adjuv
use
formul
mice
rhesu
macaqu
hrv
vaccin
immunogen
relat
suffici
quantiti
input
antigen
valenc
major
factor
potenc
breadth
respons
thu
gener
vaccin
capabl
induc
nab
respons
numer
divers
hrv
type
h
rv
caus
respiratori
ill
billion
peopl
annual
socioeconom
burden
hrv
also
caus
pneumonia
hospit
children
adult
exacerb
asthma
chronic
obstruct
pulmonari
diseas
copd
hrv
found
second
lead
caus
communityacquir
pneumonia
requir
hospit
us
children
second
respiratori
syncyti
viru
common
pathogen
associ
pneumonia
hospit
us
adult
vaccin
hrv
could
allevi
seriou
diseas
asthma
copd
reduc
pneumonia
hospit
widespread
benefit
societi
whole
decad
ago
research
identifi
inactiv
hrv
protect
vaccin
defin
virusneutr
antibodi
nab
correl
protect
estim
durat
immun
trial
monoval
hrv
vaccin
demonstr
protect
homolog
challeng
diseas
achiev
formalininactiv
viru
given
intramuscularli
im
intranas
humor
immun
heterolog
viru
type
observ
though
crossreact
cell
promot
clearanc
limit
crossneutr
antibodi
induc
hyperimmun
anim
possibl
vaccin
compos
distinct
hrv
antigen
view
formid
imposs
two
main
challeng
gener
broad
immun
respons
feasibl
compos
vaccin
ab
repertoir
theoret
immens
vaccin
clinic
use
thought
work
via
polyclon
ab
respons
deepsequenc
human
ab
gene
follow
vaccin
influenza
viru
found
thousand
ab
lineag
whole
pathogen
polyval
vaccin
carri
natur
immunogen
take
advantag
capac
valenc
increas
pneumococc
human
papillomaviru
viru
vaccin
recent
year
given
signific
hrv
test
polyval
hrv
vaccin
three
speci
hrv
b
c
sequenc
method
defin
type
b
type
c
type
thought
serolog
distinct
hrv
type
hrv
c
associ
asthma
exacerb
acut
diseas
hrv
b
hrv
c
discov
ref
recent
cultur
cell
focus
hrv
preval
speci
permiss
anim
challeng
model
hrv
viru
replic
mice
cotton
rat
recapitul
aspect
hrv
pathogenesi
best
efficaci
model
human
challeng
monoval
vaccin
trial
formalininactiv
valid
clinic
test
assess
induct
nab
guinea
pig
reciproc
serum
nab
titr
result
four
dose
dilut
vaccin
correl
vaccin
efficaci
human
although
nab
titr
requir
protect
defin
earli
studi
establish
inactiv
hrv
protect
human
immunogen
anim
inform
clinic
test
show
polyval
inactiv
hrv
vaccin
gener
broad
nab
respons
balbc
mous
model
well
rhesu
macaqu
rm
model
immunogen
polyval
inactiv
hrv
vaccin
affect
increas
valenc
relat
antigen
dose
highli
polyval
strategi
may
facilit
practic
hrv
vaccin
develop
immunogen
hrv
vaccin
mice
first
use
balbc
mice
test
immunogen
propag
hrv
cell
inactiv
infect
use
formalin
sera
naiv
mice
detect
nab
fig
alum
adjuv
enhanc
nab
respons
induc
im
inactiv
fig
effect
valenc
compar
nab
respons
induc
inactiv
type
vaccin
fig
tissu
cultur
infecti
dose
tcid
titr
input
virus
inactiv
inactivatedtcid
provid
supplementari
tabl
origin
antigen
sin
occur
sequenti
exposur
relat
viru
variant
result
bias
immun
type
encount
first
bival
hrvimmun
mice
observ
modest
origin
antigen
sin
follow
prime
vaccin
inactiv
hrv
boost
vaccin
partial
allevi
effect
supplementari
fig
similar
influenza
viru
collect
result
prompt
us
explor
fulli
nab
respons
polyval
hrv
vaccin
suffici
input
hrv
titr
determin
immunogen
report
two
differ
inactiv
hrv
prepar
induc
nab
titr
input
viru
type
recipi
subject
howev
input
titr
virus
inactiv
rang
tcid
per
ml
dilut
gener
ml
dose
given
im
prime
boost
adjuv
hypothes
low
input
antigen
dose
respons
poor
nab
respons
inactiv
hrv
reconstitut
vaccin
close
possibl
avail
hrv
type
inactivatedtcid
per
vaccin
dose
compar
vaccin
type
input
titr
rang
inactivatedtcid
per
dose
reconstitut
vaccin
result
detect
nab
prime
vaccin
follow
boost
vaccin
nab
five
type
highest
input
titr
fig
high
titr
vaccin
result
nab
type
prime
vaccin
type
boost
fig
follow
boost
vaccin
appear
inactivatedtcid
per
vaccin
dose
threshold
induct
nab
model
fig
titr
correl
input
load
nab
induct
immunogen
hrv
vaccin
mice
inject
vaccin
use
peopl
commonli
given
ml
dose
facil
highest
allow
im
vaccin
volum
mice
ml
test
per
ml
hrv
vaccin
mice
scalabl
prototyp
inactiv
hrv
vaccin
lower
averag
inactivatedtcid
per
type
per
dose
composit
supplementari
tabl
accommod
volum
adjust
inactiv
hrv
vaccin
induc
nab
input
type
follow
prime
boost
fig
nab
induc
inactiv
hrv
persist
day
postboost
supplementari
fig
use
two
differ
set
viru
stock
prime
boost
vaccin
experi
supplementari
tabl
reason
interim
prime
boost
vaccin
obtain
higher
titr
viru
stock
eleven
input
type
higher
titr
stock
eleven
use
boost
vaccin
inactiv
hrv
prime
vaccin
induc
nab
viru
type
boost
result
nab
type
fig
averag
nab
titr
result
prime
boost
data
demonstr
broad
neutral
divers
hrv
type
straightforward
vaccin
approach
tabl
vaccin
induc
nab
rm
rm
b
input
virus
follow
prime
vaccin
fig
vaccin
induc
nab
rm
c
rm
input
virus
follow
prime
vaccin
fig
breadth
nab
follow
prime
vaccin
rm
superior
observ
mice
may
due
anim
speci
differ
andor
higher
inactivatedtcid
input
titr
rm
vaccin
follow
boost
vaccin
serum
nab
titr
type
hrvvaccin
rm
fig
viru
type
hrvvaccin
rm
fig
averag
nab
titr
result
prime
boost
rm
nab
respons
typespecif
crossneutr
minim
nab
induc
vaccin
nonvaccin
type
supplementari
fig
nab
respons
inactiv
hrv
vaccin
broad
potent
rm
hrv
yield
cell
semipurif
hplc
hrv
stock
use
vaccin
produc
cell
good
substrat
hrv
replic
suitabl
vaccin
manufactur
compar
infecti
yield
hrv
type
qualifi
vaccin
product
adequ
yield
obtain
cell
supplementari
fig
inject
vaccin
requir
defin
puriti
proof
principl
semipurifi
three
hrv
type
highperform
liquid
chromatographi
found
uncompromis
immunogen
trival
inactiv
semipurifi
hrv
mice
supplementari
fig
studi
demonstr
polyval
inactiv
hrv
vaccin
expand
composit
alum
adjuv
immunogen
approxim
onethird
circul
hrv
type
although
fifti
hrv
type
minor
data
provid
proof
principl
highli
polyval
vaccin
approach
forti
year
ago
prospect
polyval
hrv
vaccin
dour
good
reason
howev
progress
technolog
advanc
complex
vaccin
render
impedi
polyval
hrv
vaccin
manag
scaleup
hrv
vaccin
may
facilit
relat
vaccin
product
process
new
costsav
manufactur
technolog
inactiv
hrv
posit
histori
clinic
efficaci
basi
result
dose
earli
immunogen
hrv
vaccin
estim
inactivatedtcid
per
type
per
dose
use
therefor
hrv
stock
tcid
per
ml
requir
potenti
hrv
formul
ml
dose
contain
alum
adjuv
futur
studi
hope
produc
comprehens
hrv
vaccin
limit
studi
includ
hrv
c
antigen
import
hrv
vaccin
develop
especi
paediatr
popul
ongo
effort
aim
propag
hrv
c
strain
high
titr
cell
line
develop
serolog
assay
ultim
approach
may
lead
vaccin
rhinovirusmedi
diseas
includ
asthma
copd
exacerb
common
cold
advanc
valenc
may
applic
vaccin
antigen
variabl
pathogen
cell
line
virus
cell
obtain
american
type
cultur
collect
atcc
cultur
minim
essenti
media
richter
modif
phenol
red
mem
thermo
fisher
supplement
fetal
bovin
serum
cell
line
authent
commonli
misidentifi
intern
cell
line
authent
committe
test
cell
use
lookout
mycoplasma
detect
kit
sigma
mycoplasma
neg
hrv
hrv
propag
titrat
hrv
stock
gener
cell
approxim
ml
hrv
inocul
onto
subconflu
monolay
cell
flask
adsorpt
h
room
temperatur
rock
ml
hrv
infect
medium
mem
supplement
fb
mm
hepe
mm
mgcl
nonessenti
amino
acid
gibco
catalog
ad
infect
allow
proceed
co
humidifi
incub
monolay
appear
complet
involv
cytopath
effect
cpe
day
postinfect
cell
scrape
cell
medium
ml
transfer
two
prechil
ml
conic
polypropylen
tube
kept
ice
suspens
sonic
use
sonic
dismembr
model
fisher
scientif
equip
diamet
horn
disrupt
diamet
taper
microtip
secur
ring
stand
sonic
perform
oper
close
room
ear
protect
amplitud
interv
puls
per
ml
materi
sonic
yield
higher
titr
freezethaw
suspens
clarifi
centrifug
min
supernat
transfer
cryovial
snapfrozen
liquid
nitrogen
store
compar
hrv
yield
cell
flask
subconflu
cell
infect
multipl
infect
tcid
per
cell
ml
cultur
medium
discard
scrape
cell
remain
ml
follow
sonic
stock
tcid
ml
titr
determin
infect
subconflu
cell
plate
serial
dilut
sampl
stain
cell
day
postinfect
crystal
methanol
score
well
cpe
calcul
end
point
titr
use
reed
muench
method
hrv
purif
hrv
stock
collect
cell
monolay
describ
clarifi
brief
centrifug
low
speed
remov
larg
cellular
debri
min
remov
excess
albumin
crude
viru
stock
affin
chromatographi
supernat
load
onto
hitrap
blue
hp
column
ge
healthcar
use
kta
purifi
system
ge
healthcar
accord
manufactur
specif
flowthrough
subsequ
load
hitrap
capto
core
column
ge
healthcar
refin
viru
prep
size
exclus
chromatographi
flowthrough
hitrap
blue
hp
hitrap
capto
core
captur
use
kta
purifi
system
ge
healthcar
mm
sodium
phosphat
buffer
ph
flowthrough
size
exclus
chromatographi
dialyz
overnight
trishcl
buffer
ph
load
onto
hitrap
q
xl
column
ge
healthcar
separ
fraction
ion
exchang
chromatographi
viruscontain
fraction
elut
use
kta
purifi
system
ge
healthcar
trishcl
buffer
ph
sodium
chlorid
gradient
fraction
show
high
absorpt
peak
nm
collect
analys
viral
titr
tcid
end
point
dilut
assay
fraction
puriti
visual
sdspage
gel
silver
stain
thermo
fisher
scientif
supplementari
fig
supplementari
tabl
fraction
high
viru
titr
puriti
combin
formalin
inactiv
describ
mice
rm
experi
involv
anim
perform
emori
univers
yerk
nation
primat
research
center
accord
guidelin
establish
anim
welfar
act
nih
guid
care
use
laboratori
anim
anim
facil
emori
univers
yerk
center
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
aaalac
institut
anim
care
use
committe
iacuc
emori
univers
approv
studi
pathogenfre
femal
balbc
mice
purchas
jackson
laboratori
bar
harbor
usa
mice
randomli
assign
group
base
sequenti
select
inventori
investig
blind
outcom
assess
statist
method
use
predetermin
sampl
size
young
adult
kg
year
age
femal
male
indian
rm
macaca
mulatta
rm
maintain
accord
nih
guidelin
yerk
nation
primat
research
center
handl
movement
rm
perform
qualifi
personnel
receiv
specif
train
safe
human
method
anim
handl
yerk
nation
primat
research
center
initi
exclus
criterion
preexist
nab
hrv
studi
perform
strict
accord
us
depart
agricultur
regul
recommend
guid
care
use
laboratori
anim
nih
rm
alloc
unblind
manner
two
vaccin
group
one
male
one
femal
per
group
statist
method
use
predetermin
sampl
size
vaccin
immun
hrv
type
inactiv
addit
formalin
follow
incub
stir
h
previous
describ
hrv
vaccin
complet
inactiv
infect
confirm
end
point
tcid
titrat
cell
formalin
inactiv
method
result
greater
immunogen
mice
altern
inactiv
bpropiolacton
suggest
formalin
inactiv
preserv
antigen
determin
mice
vaccin
im
inactiv
hrv
strain
mix
mg
alhydrogel
adjuv
aluminium
hydroxid
wet
gel
suspens
alum
sigma
catalog
invivogen
catalog
vacalu
accord
instruct
manufactur
total
volum
per
mous
ml
administ
ml
per
thigh
mice
given
second
ident
vaccin
boost
time
indic
figur
legend
rm
vaccin
im
inactiv
hrv
strain
mix
mg
alhydrogel
adjuv
total
volum
per
rm
ml
administ
one
leg
rm
boost
ident
vaccin
four
week
serum
collect
mice
peripher
blood
collect
microcentrifug
tube
submandibular
vein
sampl
incub
room
temperatur
min
clot
tube
centrifug
min
separ
serum
serum
sampl
pool
mice
group
store
use
phlebotomi
involv
rm
perform
either
ketamin
mg
kg
telazol
mg
kg
anaesthesia
fast
anim
follow
anaesthesia
ketamin
telazol
anim
bled
femor
vein
yerk
blood
collect
guidelin
follow
ml
kg
per
day
blood
collect
collect
blood
serum
separ
tube
sampl
incub
room
temperatur
min
tube
centrifug
min
separ
serum
serum
sampl
individu
rm
store
use
serum
neutral
assay
cell
seed
plate
attain
confluenc
h
due
limit
volum
mous
serum
per
bleed
number
nab
assay
requir
pool
mous
sera
separ
serum
whole
blood
equal
volum
sera
per
mous
pool
group
heat
inactiv
level
nab
indic
hrv
type
vaccin
use
mice
measur
pool
sera
heatinactiv
min
serum
sampl
twofold
serial
dilut
mem
ad
tcid
ml
hrv
type
test
equal
volum
viru
serum
mixtur
incub
h
ml
serumviru
mixtur
transfer
onto
cell
monolay
plate
triplic
plate
spinocul
min
type
noserum
control
ad
test
input
tcid
test
pool
antisera
assay
standard
spinocul
ml
hrv
infect
medium
ad
well
plate
incub
day
co
stain
crystal
violet
describ
well
score
presenc
absenc
cpe
neutral
antibodi
end
point
titr
confid
interv
determin
method
reed
muench
previous
describ
hrv
confid
interv
indic
variabl
three
technic
replic
within
singl
nab
experi
exampl
nab
assay
titr
calcul
provid
supplementari
fig
data
avail
primari
data
support
find
studi
avail
correspond
author
request
